Serina Therapeutics, Inc. Comprehensive Income
Serina Therapeutics, Inc. (SER) reported Comprehensive Income of -$6.35 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-13
- Serina Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$6.35M.
- Serina Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$6.89M.
- Serina Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$3.35M.
- Serina Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$4.59M, a 425.46% decline year-over-year.
- Serina Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$19.20M.
- Serina Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$11.14M.
- Serina Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$10.52M.
- Serina Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2021 was -$8.83M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$6.35M 10-Q · filed 2026-08-13 | -$13.24M 10-Q · filed 2026-08-13 | -$16.59M derived: sum of 3 quarters · filed 2026-08-13 | -$21.18M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | -$6.89M 10-Q · filed 2026-05-14 | -$10.24M derived: sum of 2 quarters · filed 2026-05-14 | -$14.83M derived: sum of 3 quarters · filed 2026-05-14 | -$21.27M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | -$3.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$7.93M derived: sum of 2 quarters · filed 2026-03-25 | -$14.38M derived: sum of 3 quarters · filed 2026-08-13 | -$19.20M 10-K · filed 2026-03-25 | ||
| 2025-09-30 | -$4.59M 10-Q · filed 2025-11-13 | -$11.04M derived: sum of 2 quarters · filed 2026-08-13 | -$15.85M 10-Q · filed 2025-11-13 | -$18.59M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | -$6.45M 10-Q · filed 2026-08-13 | -$11.26M 10-Q · filed 2026-08-13 | -$14.00M derived: sum of 3 quarters · filed 2026-08-13 | -$12.59M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | -$4.81M 10-Q · filed 2026-05-14 | -$7.55M derived: sum of 2 quarters · filed 2026-05-14 | -$6.14M derived: sum of 3 quarters · filed 2026-05-14 | |||
| 2024-12-31 | -$2.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$1.33M derived: sum of 2 quarters · filed 2026-03-25 | -$11.14M 10-K · filed 2026-03-25 | |||
| 2024-09-30 | $1.41M 10-Q · filed 2025-11-13 | -$8.40M 10-Q · filed 2025-11-13 | ||||
| 2023-03-31 | -$3.29M 10-Q · filed 2023-05-12 | -$6.05M derived: sum of 2 quarters · filed 2023-05-12 | -$8.48M derived: sum of 3 quarters · filed 2023-05-12 | -$11.10M derived: sum of 4 quarters · filed 2023-05-12 | ||
| 2022-12-31 | -$2.76M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$5.20M derived: sum of 2 quarters · filed 2023-03-31 | -$7.82M derived: sum of 3 quarters · filed 2023-03-31 | -$10.52M 10-K · filed 2023-03-31 | ||
| 2022-09-30 | -$2.44M 10-Q · filed 2022-11-10 | -$5.05M derived: sum of 2 quarters · filed 2022-11-10 | -$7.76M 10-Q · filed 2022-11-10 | -$9.92M derived: sum of 4 quarters · filed 2023-05-12 | ||
| 2022-06-30 | -$2.62M 10-Q · filed 2022-08-12 | -$5.33M 10-Q · filed 2022-08-12 | -$7.48M derived: sum of 3 quarters · filed 2023-05-12 | -$9.44M derived: sum of 4 quarters · filed 2023-05-12 | ||
| 2022-03-31 | -$2.71M 10-Q · filed 2023-05-12 | -$4.87M derived: sum of 2 quarters · filed 2023-05-12 | -$6.82M derived: sum of 3 quarters · filed 2023-05-12 | -$9.30M derived: sum of 4 quarters · filed 2023-05-12 | ||
| 2021-12-31 | -$2.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$4.11M derived: sum of 2 quarters · filed 2023-03-31 | -$6.59M derived: sum of 3 quarters · filed 2023-03-31 | -$8.83M 10-K · filed 2023-03-31 | ||
| 2021-09-30 | -$1.96M 10-Q · filed 2022-11-10 | -$4.43M derived: sum of 2 quarters · filed 2022-11-10 | -$6.67M 10-Q · filed 2022-11-10 | -$9.08M derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2021-06-30 | -$2.48M 10-Q · filed 2022-08-12 | -$4.71M 10-Q · filed 2022-08-12 | -$7.12M derived: sum of 3 quarters · filed 2022-08-12 | -$9.68M derived: sum of 4 quarters · filed 2022-08-12 | ||
| 2021-03-31 | -$2.24M 10-Q · filed 2022-05-13 | -$4.65M derived: sum of 2 quarters · filed 2022-05-13 | -$7.20M derived: sum of 3 quarters · filed 2022-05-13 | -$9.89M derived: sum of 4 quarters · filed 2022-05-13 | ||
| 2020-12-31 | -$2.41M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | -$4.96M derived: sum of 2 quarters · filed 2022-03-29 | -$7.66M derived: sum of 3 quarters · filed 2022-03-29 | -$10.90M 10-K · filed 2022-03-29 | ||
| 2020-09-30 | -$2.55M 10-Q · filed 2021-11-12 | -$5.25M derived: sum of 2 quarters · filed 2021-11-12 | -$8.49M 10-Q · filed 2021-11-12 | -$11.24M derived: sum of 4 quarters · filed 2021-11-12 | ||
| 2020-06-30 | -$2.69M 10-Q · filed 2021-08-13 | -$5.94M 10-Q · filed 2021-08-13 | -$8.69M derived: sum of 3 quarters · filed 2021-08-13 | -$11.93M derived: sum of 4 quarters · filed 2021-08-13 | ||
| 2020-03-31 | -$3.25M 10-Q · filed 2021-05-17 | -$3.35M 10-Q · filed 2020-05-14 | -$5.99M derived: sum of 2 quarters · filed 2021-05-17 | -$9.24M derived: sum of 3 quarters · filed 2021-05-17 | -$12.38M derived: sum of 4 quarters · filed 2021-05-17 | |
| 2019-12-31 | -$2.75M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$5.99M derived: sum of 2 quarters · filed 2021-03-31 | -$9.13M derived: sum of 3 quarters · filed 2021-03-31 | -$12.31M 10-K · filed 2021-03-31 | ||
| 2019-09-30 | -$3.25M 10-Q · filed 2020-11-16 | -$6.38M derived: sum of 2 quarters · filed 2020-11-16 | -$9.57M 10-Q · filed 2020-11-16 | -$12.87M derived: sum of 4 quarters · filed 2020-11-16 | ||
| 2019-06-30 | -$3.13M 10-Q · filed 2020-08-14 | -$6.32M 10-Q · filed 2020-08-14 | -$9.62M derived: sum of 3 quarters · filed 2020-08-14 | -$11.80M derived: sum of 4 quarters · filed 2020-08-14 | ||
| 2019-03-31 | -$3.19M 10-Q · filed 2020-05-14 | -$6.49M derived: sum of 2 quarters · filed 2020-05-14 | -$8.67M derived: sum of 3 quarters · filed 2020-05-14 | -$10.66M derived: sum of 4 quarters · filed 2020-05-14 | ||
| 2018-12-31 | -$3.30M derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-03-31 | -$5.48M derived: sum of 2 quarters · filed 2020-03-31 | -$7.48M derived: sum of 3 quarters · filed 2020-03-31 | -$7.80M 10-K/A · filed 2020-03-31 | $7.80M 10-K · filed 2019-04-01 | |
| 2018-09-30 | -$2.18M 10-Q · filed 2019-11-14 | -$4.18M derived: sum of 2 quarters · filed 2019-11-14 | -$4.50M 10-Q · filed 2019-11-14 | |||
| 2018-06-30 | -$2.00M 10-Q · filed 2019-08-14 | -$2.32M 10-Q · filed 2019-08-14 | ||||
| 2018-03-31 | -$322.00K 10-Q · filed 2019-05-15 | |||||
| 2017-12-31 | $6.63M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |